Meloxicam
Non-steroidal anti-inflammatory drug (NSAID)
Meloxicam
Forms and strengths
Form: TabletStrength: 7.5 mg, 15 mg
References
Indication
- Meloxicam is used to relieve the symptoms of rheumatoid arthritis in adults.
- Meloxicam is used to relieve painful osteoarthritis (degenerative joint disease) in adults.
- As an NSAID, meloxicam only controls pain and inflammation for as long as it is taken; it does not treat the underlying joint disease or slow its progression.
Pregnancy
Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.
- Meloxicam is contraindicated during the third trimester of pregnancy because it can cause premature closure of a fetal blood vessel (the ductus arteriosus) and can prolong labour.
- Caution is needed if meloxicam is used during the first and second trimesters, particularly from around 20 weeks of pregnancy onward, because NSAIDs can reduce fetal urine output and lead to low amniotic fluid (oligohydramnios) and, in some cases, impaired newborn kidney function.
- Use in early pregnancy has been linked in epidemiological data to a modestly increased risk of miscarriage and of certain birth defects, including heart and abdominal wall malformations.
- Meloxicam may delay ovulation and impair fertility, so it is not recommended for women who are trying to conceive or being investigated for infertility.
Breastfeeding
- Meloxicam is contraindicated while breastfeeding, since NSAIDs pass into breast milk and could cause harm to a nursing infant.
Geriatrics
- Older adults are more prone to NSAID-related side effects, including serious gastrointestinal bleeding, and should generally start meloxicam at a lower dose under close supervision.
- Elderly patients are more likely to have reduced kidney, liver, or heart function, which increases the risk of complications from meloxicam.
Pediatrics
- Meloxicam is contraindicated in children and adolescents under 18 years of age, as its safety and effectiveness have not been established in this population.
Dosage & Administration
- For painful osteoarthritis, the usual dose of meloxicam is 7.5 mg once daily, which may be increased to 15 mg once daily if needed.
- For rheumatoid arthritis, the usual dose of meloxicam is 15 mg once daily, which may be reduced to 7.5 mg once daily depending on response.
- Patients at higher risk of side effects, such as those with a history of gastrointestinal disease, cardiovascular risk factors, older adults, or people with reduced kidney function, should start at 7.5 mg once daily.
- The maximum recommended daily dose of meloxicam is 15 mg.
- No dose adjustment is needed for mild to moderate liver impairment, but meloxicam is contraindicated in severe liver impairment or active liver disease.
- No dose reduction is needed for mild or moderate kidney impairment; meloxicam is contraindicated in non-dialysed patients with severe kidney impairment, and the dose should not exceed 7.5 mg per day in patients on hemodialysis.
- If a dose is missed, the regular schedule should simply be resumed the next day; an extra dose should not be taken to make up for it.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Meloxicam overdose typically causes lethargy, drowsiness, nausea, vomiting, and stomach pain, which usually resolve with supportive care.
- Gastrointestinal bleeding can occur after an overdose.
- Severe poisoning may cause high blood pressure, acute kidney failure, liver dysfunction, slowed breathing, coma, seizures, cardiovascular collapse, or cardiac arrest.
- Allergic-type (anaphylactoid) reactions have been reported after an overdose.
- Management is supportive; gastric lavage may help if performed within an hour of ingestion, and activated charcoal is recommended for patients seen within 1 to 2 hours, with repeat doses for large or symptomatic overdoses.
- Cholestyramine can speed the elimination of meloxicam and may be used after an overdose, whereas forced diuresis, urine alkalinization, hemodialysis, and hemoperfusion are not expected to help because meloxicam is highly protein-bound.
Common side effects
- Indigestion (dyspepsia) may occur.
- Nausea may occur.
- Abdominal pain may occur.
- Diarrhea may occur.
- Constipation may occur.
- Flatulence may occur.
- Skin rash may occur.
- Light-headedness or dizziness may occur.
- Headache may occur.
- Swelling (edema) of the legs or ankles may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Meloxicam can cause serious gastrointestinal ulcers, perforation, or bleeding, which can occur without warning symptoms.
- Meloxicam can increase the risk of heart attack, stroke, or other blood clot-related events, and can worsen or trigger congestive heart failure.
- Meloxicam can trigger asthma attacks or bronchospasm, particularly in people sensitive to ASA or other NSAIDs.
- Serious allergic reactions, including angioedema and anaphylactic/anaphylactoid shock, can occur even in people who have tolerated NSAIDs before.
- Kidney problems, including acute kidney failure, interstitial nephritis, and blood in the urine, can occur.
- Visual disturbances, including blurred vision, can occur and warrant an eye examination.
- Urinary problems, including difficulty urinating or urinary retention, can occur.
- Liver problems, including jaundice, hepatitis, and rare cases of liver failure, can occur.
- Aseptic meningitis, with stiff neck, severe headache, nausea, vomiting, or confusion, has rarely been reported, particularly in people with autoimmune disease.
- Confusion, depression, and other mood or thinking changes have been reported.
- Ringing in the ears (tinnitus) or hearing changes have been reported.
- Serious skin reactions, including DRESS syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme, can occur, most often within the first month of treatment.
- Blood disorders, including agranulocytosis, low white blood cell counts, low platelet counts, and aplastic anemia, have rarely been reported.
- Seek urgent medical attention for signs of a serious gastrointestinal bleed (black or bloody stools, vomiting blood), chest pain, sudden weakness, severe skin rash or blistering, or difficulty breathing.
Use with caution
- Use with caution in patients with cardiovascular risk factors such as high blood pressure, high cholesterol, diabetes, smoking, or existing heart or vascular disease.
- Use with caution in patients with a history of stomach ulcers or gastrointestinal bleeding, since the risk of a repeat bleed is substantially higher.
- Use with caution in patients with reduced kidney function, and monitor kidney function during treatment.
- Use with caution in patients with liver impairment, using close observation if treatment is necessary.
- Use with caution in frail, debilitated, or elderly patients, who tolerate side effects less well.
- Use with caution in patients taking anticoagulants or antiplatelet drugs, due to an increased risk of bleeding.
- Use with caution when combined with low-dose ASA for heart protection, since this combination increases the risk of gastrointestinal ulceration.
- Use with caution in patients prone to fluid retention, including those with heart failure or high blood pressure, since meloxicam can cause sodium and fluid retention.
- Use with caution in patients with a history of asthma, nasal polyps, or reactions to ASA or other NSAIDs, due to the risk of cross-sensitivity.
- Use with caution in dehydrated patients, who should be rehydrated before starting meloxicam.
Contraindications
- Contraindicated in the peri-operative period of coronary artery bypass graft (CABG) surgery.
- Contraindicated during the third trimester of pregnancy.
- Contraindicated in women who are breastfeeding.
- Contraindicated in patients with severe, uncontrolled heart failure.
- Contraindicated in patients with known hypersensitivity to meloxicam or to any ingredient in the product.
- Contraindicated in patients with a history of asthma attacks, hives, or other allergic reactions triggered by ASA or other NSAIDs.
- Contraindicated in patients with active or recent gastrointestinal ulceration, perforation, or bleeding.
- Contraindicated in patients with cerebrovascular bleeding or other bleeding disorders.
- Contraindicated in patients with inflammatory bowel disease, including Crohn's disease or ulcerative colitis.
- Contraindicated in patients with severe liver impairment or active liver disease.
- Contraindicated in patients with severe kidney impairment (creatinine clearance under 30 mL/min) or worsening kidney disease.
- Contraindicated in patients with known high blood potassium (hyperkalemia).
- Contraindicated in children and adolescents under 18 years of age.
Drug interactions
- Combining meloxicam with ASA or other NSAIDs is not recommended, as it increases the risk of gastrointestinal ulcers and bleeding without added benefit.
- Meloxicam can increase the anticoagulant effect and bleeding risk of warfarin; INR should be monitored closely, especially when starting or stopping meloxicam.
- Meloxicam may increase the blood-sugar-lowering effect of sulfonylureas or nateglinide, raising the risk of low blood sugar.
- Meloxicam can reduce the blood-pressure-lowering effect of ACE inhibitors and angiotensin-II receptor blockers, and combining these drugs increases the risk of acute kidney failure and high potassium.
- Combining meloxicam with anticoagulants, other antiplatelet drugs, or thrombolytics increases the risk of bleeding.
- Cholestyramine speeds the clearance of meloxicam from the body.
- Meloxicam may increase the kidney toxicity of cyclosporine or tacrolimus.
- Meloxicam can blunt the salt-eliminating effect of furosemide and thiazide diuretics, and combined use requires monitoring of kidney function.
- Combining meloxicam with oral glucocorticoids increases the risk of gastrointestinal ulceration and bleeding.
- Meloxicam can raise lithium levels to the point of toxicity, so this combination is not recommended; if unavoidable, lithium levels should be monitored closely.
- Meloxicam can increase methotrexate levels and toxicity, particularly at high methotrexate doses, and this combination is not recommended for patients on high-dose methotrexate; blood counts and kidney function should be monitored if combined use is necessary.
- Meloxicam can increase blood levels of pemetrexed and the risk of blood toxicity; if the combination is needed, meloxicam should be paused around the time of pemetrexed administration in patients with reduced kidney function.
- Combining meloxicam with SSRIs (such as citalopram, fluoxetine, paroxetine, or sertraline) increases the risk of gastrointestinal bleeding.
- No pharmacokinetic interaction was seen between meloxicam and antacids or cimetidine.
Food interactions
- Meloxicam can be taken with or without food; food does not reduce how much of the drug is absorbed, though a high-fat meal can modestly raise and delay the peak blood level.
Time of administration
- Meloxicam is taken once daily and may be taken at any time of day, with or without food, without regard to meal timing.
Storage
- Store meloxicam tablets at room temperature (15°C to 30°C) in a dry place.
Patient take-away
- Take meloxicam at the lowest effective dose for the shortest time needed to control symptoms.
- Do not combine meloxicam with other NSAIDs, including over-the-counter ibuprofen or naproxen, unless directed by a doctor.
- Stop taking meloxicam and seek medical care right away for black or bloody stools, vomiting blood, chest pain, sudden weakness, severe rash, or swelling of the face or throat.
- Tell your doctor or pharmacist about all other medications, especially blood thinners, other NSAIDs, blood pressure medications, lithium, or methotrexate, before starting meloxicam.
- Report any new stomach pain, unusual bruising, swelling, or changes in urination to your doctor promptly.